Research Article

Radiomic Features of 18F-FDG PET in Hodgkin Lymphoma Are Predictive of Outcomes

Table 2

Characteristics of the training and validation cohorts.

Total (n = 65)Training (n = 49)Validation (n = 16)

Sex0.596
 Male45 (69.2%)34 (69.4%)11 (68.8%)
 Female20 (30.8%)15 (30.6%)5 (31.3%)

Age, median (range)29.0 (8–72)29 (8–72)30 (16–54)0.703

Ann Arbor stage0.585
 I-II36 (55.4%)27 (55.1%)9 (56.3%)
 III-IV29 (44.6%)22 (44.9%)7 (43.8%)

Bulky disease0.678
 >10 cm9 (13.8%)6 (12.2%)3 (18.8%)
 <10 cm56 (86.2%)43 (87.8%)13 (81.3%)

BM0.612
 Yes9 (13.8%)7 (14.3%)2 (12.5%)
 No56 (86.2%)42 (85.7%)14 (87.5%)

Extranodal sites0.495
 Yes25 (38.5%)20 (40.8%)5 (31.3%)
 No40 (61.5%)29 (59.2%)11 (68.8%)

B symptoms0.389
 Yes22 (33.8%)18 (36.7%)4 (25.0%)
 No43 (66.2%)31 (63.3%)12 (75.0%)

Chemotherapy with IFRT0.565
 Yes4 (6.2%)4 (8.2%)0 (0.0%)
 No61 (93.8%)45 (91.8%)16 (100.0%)

LDH, lactate dehydrogenase, BM, bone marrow; IFRT, involved-field radiation therapy.